featured
Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib in Patients With BRAF-Mutant Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF-Mutant Melanoma (COLUMBUS): A Multicentre, Open-Label, Randomised Phase 3 Trial
Lancet Oncol 2018 Mar 21;[EPub Ahead of Print], R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, C Garbe, D Schadendorf, I Krajsova, R Gutzmer, V Chiarion-Sileni, C Dutriaux, JWB de Groot, N Yamazaki, C Loquai, LA Moutouh-de Parseval, MD Pickard, V Sandor, C Robert, KT FlahertyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.